Brief: Reata Pharmaceuticals Stock Trading Halted Today FDA Advisory Committee To Discuss Bardoxolone For Treatment Of Patients With Chronic Kidney Disease Caused By Alport Syndrome
08/12/2021 12:40
Dec 8 (Reuters) - Reata Pharmaceuticals Inc RETA.O :
* REATA PHARMACEUTICALS STOCK TRADING HALTED TODAY; FDA
ADVISORY
COMMITTEE TO DISCUSS BARDOXOLONE FOR THE TREATMENT OF PATIENTS
WITH CHRONIC KIDNEY DISEASE CAUSED BY ALPORT SYNDROME
* REATA PHARMACEUTICALS INC - PRESCRIPTION DRUG USER FEE ACT
DATE
FOR COMPLETION OF REVIEW OF NDA FOR BARDOXOLONE IS FEBRUARY 25,
2022
Source text for Eikon: ID:nBw7Znd6ha
Further company coverage: RETA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reata Pharmaceuticals
See all newsReata Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Reata Pharmaceuticals Inc expected to post a loss of $2.88 a share - Earnings Preview
Brief: Biogen Inc Says If Deal Terminated Under Certain Conditions, Reata Will Be Required To Pay Biogen Termination Fee Equal To $264 Mln
U.S. STOCKS ON THE MOVE-US regional banks, Enphase, Centene
Biogen’s $7 bln deal goes smaller and safer